Dublin, Jan. 24, 2023 (GLOBE NEWSWIRE) -- The "Global Insomnia Market Size, Share & Industry Trends Analysis Report by Distribution Channel, Therapy Type, Regional Outlook and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.
The Global Insomnia Market size is expected to reach $5.7 billion by 2028, rising at a market growth of 3.9% CAGR during the forecast period.
The rise in the prevalence of distinct sleep disorders, including parasomnias as well as insomnia, and the rise in mental depression and other painful conditions, are the main factors driving the growth of the insomnia market size. Sleep issues are a result of mental depression.
As a result, an increase in mental depression among the general population contributes to the growth of the insomnia market. Furthermore, taking some medications for a chronic condition over an extended period of time has some side effects that are thought to impair a patient's ability to sleep.
Additionally, the market for insomnia is expanding due to an increase in work-related stress. The increased workload and demanding work schedules result in poor sleep. Additionally, a lot of people including security guards work odd shifts, and the manufacturing sector is open around-the-clock.
The quality and rhythm of sleep are impacted by these irregular work shifts. Also, a rise in the number of sleep diagnostics and centres for people with insomnia helps has been seen in the past few years. The centres for insomnia help people get better quality sleep, and the centres for sleep disorders are utilized as diagnostic testing facilities.
COVID-19 Impact Analysis
It is anticipated that the COVID-19 outbreak will benefit the expansion of the market for insomniac remedies. Due to improperly functioning industries brought on by the COVID-19 pandemic, many workers lost their jobs, which contributed to an increase in stress levels in society.
Additionally, some people around the world developed depression as a result of pandemic fear. As a result, the COVID-19 pandemic's increased incidence of insomnia a condition marked by stress and depression boosts the demand for drugs that treat insomnia and propel the market's expansion.
Market Growth Factors
Increasing Aging Population
According to studies, older people (defined as those 65 and older) appear to have an 11-fold increased risk of developing some types of cancer than younger people. The burden of cancer among the elderly would then increase as the world population ages over the following 20 years.
Refractive errors, cataracts, sleep issues, and hearing loss are all fairly common in older people. A large ratio of old age people is facing sleeping issues worldwide. Thus, the rise in the aging population would result in an increasing number of insomnia cases which would further support the growth of the insomnia market over the forecast period.
Increasing Healthcare Costs
Rising healthcare costs and earlier disease diagnosis because of greater awareness of treatment options are factors that are anticipated to fuel the market growth over the course of the forecast period. The increasing size and number of funds invested in the healthcare industry by governments of different countries are one of the primary drivers of the market's growth.
Governments from a number of nations boosted their investments in creating healthcare systems whenever the COVID-19 pandemic first started to spread. As the pandemic's impact lessens, various hospitals are now concentrating on using these resources to treat other severe diseases. The insomnia market is expanding as a result of rising healthcare investment.
Market Restraining Factors
High Cost Of Diagnosing And Treating Insomnia
The high cost of diagnosis and treatment is one of the major factors impeding the growth of the insomnia market. Additionally, the term 'sleeping problem' covers a wide range of illnesses that have significant detrimental effects on an individual's health and incur high societal costs.
Insomnia makes it difficult to carry out daily tasks and is associated with a heavy financial & medical burden many patients are completely disabled. Insomnia patients spent about two times as much on direct medical care each year as matched controls without condition. The market for insomnia is not expanding because of the high cost of the medication.
Key Topics Covered:
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
220.127.116.11 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies deployed in Insomnia Market
Chapter 4. Global Insomnia Market by Distribution Channel
4.1 Global Hospital Market by Region
4.2 Global Retail Market by Region
4.3 Global Others Market by Region
Chapter 5. Global Insomnia Market by Therapy Type
5.1 Global Pharmacological Market by Region
5.2 Global Non-Pharmacological Market by Region
Chapter 6. Global Insomnia Market by Region
Chapter 7. Company Profiles
7.1 Eisai Co., Ltd.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
18.104.22.168 Product Launches and Product Expansions:
22.214.171.124 Approvals and Trails:
7.2 Takeda Pharmaceutical Company Limited
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
126.96.36.199 Approvals and Trails:
7.3 Vanda Pharmaceuticals, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Research & Development Expenses
7.3.4 Recent strategies and developments:
188.8.131.52 Approval and Trails:
7.4 Cadila Healthcare Ltd. (Zydus Cadila)
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
184.108.40.206 Product Launches and Product Expansions:
7.5 Sanofi S.A.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
220.127.116.11 Geographical Expansions:
7.6 Merck Group
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.7 Pfizer, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional & Segmental Analysis
7.7.4 Research & Development Expense
7.8 Viatris, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 Currax Pharmaceuticals LLC (Currax Holdings USA LLC)
7.9.1 Company Overview
7.9.2 Recent strategies and developments:
18.104.22.168 Acquisition and Mergers:
22.214.171.124 Geographical Expansions:
7.10. Purdue Pharma L.P.
7.10.1 Company Overview
For more information about this report visit https://www.researchandmarkets.com/r/39a8v
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900